Corrigendum to Candidate anti-tuberculosis medicines and regimens under clinical evaluation (Clinical Microbiology and Infection, (2024), 30, 9, (1131-1138), (S1198743X24002969), 10.1016/j.cmi.2024.06.016)

The authors regret that the following text on funding of this work was not included: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. The authors would like to apologise for any inconvenience caused.